Last updated on October 2018

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).

Detailed Study Description

This is a Phase 2, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two intravenous (IV) treatment regimens of anifrolumab versus placebo while taking standard of care (SOC) treatment with mycophenolate mofetil (MMF) and corticosteroids in adult subjects with active proliferative lupus nephritis (LN).

Clinical Study Identifier: NCT02547922

Contact Investigators or Research Sites near you

Start Over

Research Site

Glendale, AZ United States
  Connect »

Research Site

Phoenix, AZ United States
  Connect »

Research Site

La Jolla, CA United States
  Connect »

Research Site

Los Angeles, CA United States
  Connect »

Research Site

Thousand Oaks, CA United States
  Connect »

Research Site

Aurora, CO United States
  Connect »

Research Site

Denver, CO United States
  Connect »

Research Site

DeBary, FL United States
  Connect »

Research Site

Atlanta, GA United States
  Connect »

Research Site

Des Moines, IA United States
  Connect »

Research Site

Boston, MA United States
  Connect »

Research Site

Newark, NJ United States
  Connect »

Research Site

Great Neck, NY United States
  Connect »

Research Site

New York, NY United States
  Connect »

Research Site

Rosedale, NY United States
  Connect »

Research Site

Syracuse, NY United States
  Connect »

Research Site

Charlotte, NC United States
  Connect »

Research Site

Columbus, OH United States
  Connect »

Research Site

Oklahoma City, OK United States
  Connect »

Research Site

Philadelphia, PA United States
  Connect »

Research Site

Pittsburgh, PA United States
  Connect »

Research Site

Memphis, TN United States
  Connect »

Research Site

Buenos Aires, Argentina
  Connect »

Research Site

Cordoba, Argentina
  Connect »

Research Site

Rosario, Argentina
  Connect »

Research Site

Adelaide, Australia
  Connect »

Research Site

Clayton, Australia
  Connect »

Research Site

Herston, Australia
  Connect »

Research Site

Liverpool BC, Australia
  Connect »

Research Site

Parkville, Australia
  Connect »

Research Site

Westmead, Australia
  Connect »

Research Site

Woolloongabba, Australia
  Connect »

Research Site

Brussels, Belgium
  Connect »

Research Site

Bruxelles, Belgium
  Connect »

Research Site

Bordeaux Cedex, France
  Connect »

Research Site

Marseille, France
  Connect »

Research Site

Paris Cedex 14, France
  Connect »

Research Site

Pierre Benite Cedex, France
  Connect »

Research Site

Saint-Etienne Cedex 2, France
  Connect »

Research Site

Strasbourg, France
  Connect »

Research Site

Toulouse, France
  Connect »

Research Site

Budapest, Hungary
  Connect »

Research Site

Debrecen, Hungary
  Connect »

Research Site

Reggio Emilia, Italy
  Connect »

Research Site

Daegu, Korea, Republic of
  Connect »

Research Site

Gwangju, Korea, Republic of
  Connect »

Research Site

Seoul, Korea, Republic of
  Connect »

Research Site

Suwon-si, Korea, Republic of
  Connect »

Research Site

Chihuahua, Mexico
  Connect »

Research Site

Guadalajara, Mexico
  Connect »

Research Site

Szczecin, Poland
  Connect »

Research Site

Warszawa, Poland
  Connect »

Research Site

Bronx, NY United States
  Connect »

Research Site

New Hyde Park, NY United States
  Connect »

Research Site

München, Germany
  Connect »

Research Site

Kaposvár, Hungary
  Connect »

Research Site

San Luis Potosí, Mexico
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.